Pharmacotherapy in Adolescents

GLP-1 Receptor Agonists (2026 Review, PMC) and What Changes in Clinical Practice

Lea este articulo en español: Version Español

Pediatric obesity is linked to insulin resistance, dyslipidemia, hypertension, sleep apnea, liver disease, and psychosocial burden; when it persists through adolescence, “tracking” into adulthood raises lifetime risk of type 2 diabetes and cardiovascular disease. Treatment is therefore chronic-care: clear definitions, proactive comorbidity screening, intensive family-based intervention, and—when indicated—pharmacotherapy. In that context, GLP‑1 receptor agonists (GLP‑1 RAs) represent a paradigm shift. Therapeutically, they modulate the gut–brain axis (slowing gastric emptying and activating anorexigenic neural circuits), lowering hunger while improving metabolic markers (https://pmc.ncbi.nlm.nih.gov/articles/PMC12864059/).  

The 2026 PMC review compiles substantial clinical evidence: in adolescents, GLP‑1 RAs produce clinically meaningful BMI reductions when combined with lifestyle treatment. The review highlights striking trial outcomes: weekly semaglutide 2.4 mg plus lifestyle shows large average BMI decreases versus placebo, with many adolescents achieving ≥5% and ≥10% BMI reductions; daily liraglutide 3.0 mg also outperforms lifestyle alone, though gastrointestinal side effects are more common. A key practice point is weight regain after discontinuation in some studies—supporting the concept of chronic therapy rather than brief courses.  

My pediatric–epidemiology take is twofold. Clinically, GLP‑1 RAs can be a crucial option for adolescents with moderate-to-severe obesity and comorbidities when high-quality behavioral intervention still falls short due to biological weight-defense mechanisms; but it requires careful patient selection, expectation setting (the goal is durable cardiometabolic health), and monitoring for GI tolerance, mental health, and continuity of access. Population-wise, equity is the looming challenge: the review notes rising use in the U.S., yet still only a small fraction of adolescents with obesity receive any medication—signaling barriers in cost, insurance coverage, and availability. That risks widening disparities if only some families can sustain long-term treatment. The ethical response is not to halt innovation but to embed it within accessible intensive programs and public policies that reduce obesogenic exposures. GLP‑1 does not replace family-based care or public health; it complements them when risk is high and continuity is feasible.